For decades, ultrasound has been used to image organs such as the heart and kidneys, check blood flow, monitor the development of fetuses, reduce pain and even break up kidney stones.
Now, a Norwegian biotech company called Phoenix Solutions AS is working with the Translational Genomics Research Institute (TGen), a Phoenix, Arizona-based biomedical research facility, to test the use of these pulsed sound waves to direct and focus cancer drug therapies.
In laboratory tests, TGen will help analyze the effectiveness of a technology called Acoustic Cluster Therapy (ACT), a unique approach to targeting cancer cells by concentrating the delivery of chemotherapies, making them more effective and potentially reducing their toxicity.
Humanscan Co. Ltd., a South Korean manufacture of ultrasound diagnostic imaging, is developing clinically applicable hardware optimized for ACT, which TGen will then validate.
Phoenix Solutions is using funding from Innovation Norway to conduct this research in advance of pancreatic cancer clinical trials planned later this year.
“We are very pleased to receive this grant, which will enable us to develop and validate an optimal ultrasound platform for clinical use of ACT. In their respective fields, Humanscan and TGen both represent the cutting edge of science, and we are confident this will contribute to the clinical success of our program,” said Dr. Per Sontum, CEO of Phoenix Solutions.
TGen is a world leader in the development of novel therapeutics for the treatment of pancreatic cancer. The TGen team led the clinical development of one of the current standard-of-care regimens for this disease — nab-paclitaxel plus gemcitabine. TGen currently is involved in 13 pancreatic cancer clinical programs.
“We are pleased that this research program has become a reality, and look forward to working with ACT. The concept represents a novel approach to targeted drug delivery and looks very promising,” said Dr. Haiyong Han, a Professor in TGen’s Molecular Medicine Division and head of the Basic Research Unit in TGen’s Pancreatic Cancer Program.
Among the advantages of ultrasound technology: it is generally painless; non-invasive; does not require needles, injections or incisions; and patients are not exposed to ionizing radiation, making the procedure safer than diagnostic techniques such as X-rays and CT scans.
Humanscan CEO Sungmin Rhim said, “We are excited to enter into this collaboration with Phoenix (Solutions) and participate in the development of ACT. Ultrasound mediated, targeted drug delivery is an emerging therapy approach with great potential and we are delighted to be in the forefront of this development.”
Phoenix Solutions also is considering this technology for use in addressing other types of cancer, including: liver, prostate and triple-negative breast cancer; and other diseases, including those involving inflammation and the central nervous system.
Learn more: TGEN TESTS ULTRASOUND AS WAY TO ENHANCE CANCER DRUG DELIVERY
The Latest on: Cancer drug delivery
[google_news title=”” keyword=”cancer drug delivery” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Cancer drug delivery
- SN Bioscience Receives FDA Fast Track Designation for Small Cell Lung Canceron May 9, 2024 at 8:59 pm
SN Bioscience Co. Ltd. (CEO Park Young-hwan) announced on May 7 that the FDA has granted Fast Track Designation for small cell lung cancer (SCLC) for SNB-101 (API: SN-38), a new drug for polymer ...
- A Closed-Loop Drug-Delivery System Could Improve Chemotherapyon April 25, 2024 at 3:19 pm
New CLAUDIA system could continuously monitor patients during an infusion, adjust dosage to maintain optimal drug levels ...
- A closed-loop drug-delivery system could improve chemotherapyon April 23, 2024 at 5:00 pm
When cancer patients undergo chemotherapy ... A clinically translatable, closed-loop drug delivery system for personalized drug dosing, Med (2024). DOI: 10.1016/j.medj.2024.03.020 ...
- An effective drug delivery system for next-generation treatments to hitch a ride in cancer cellson April 16, 2024 at 9:42 am
Antisense oligonucleotides (ASOs) are next-generation drugs that can treat disease by blocking the transfer of harmful messages from our genes. In people with cancer, ASOs have the potential to ...
- An effective drug delivery system for next-generation treatments to hitch a ride in cancer cellson April 15, 2024 at 5:00 pm
"We hope that the results of our research will lead to significant progress in the development and delivery of ASOs and similar gene-targeting drugs for treating cancer," says senior author ...
- Drug Delivery News and Researchon April 15, 2024 at 5:00 pm
When cancer patients undergo chemotherapy ... University of North Carolina at Chapel Hill researchers have developed a new drug delivery platform that harnesses helical amyloid fibers designed ...
- Stimulus-responsive Macromolecules and Nanoparticles for Cancer Drug Deliveryon April 10, 2024 at 5:00 pm
Tumor-specific presentation of bioactive molecules in response to enzymatic, pH or temperature stimuli affords improved specificity and efficacy of targeted drug delivery to tumors. Reducing ...
- News tagged with drug delivery systemon January 23, 2024 at 4:00 pm
Treating complex diseases such as skin cancer often requires simultaneous administration of multiple anticancer drugs. The delivery of such life-saving therapeutic drugs has evolved with the rise ...
- Drug Delivery and Molecular Sensingon August 17, 2020 at 6:15 pm
The Drug Delivery and Molecular Sensing (DDMS) Research Program is comprised of faculty members at Purdue University with the mission of providing physical science/engineering and technology solutions ...
via Bing News